

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 JULY 2026

ERRATUM 2

This erratum advises note and caution changes for adrenaline (epinephrine) items 15359J and 15355E for 1 July 2026. The full restrictions for these items are outlined below.

This erratum corrects entries in the Summary of Changes and Schedule of Pharmaceutical Benefits pdf editions only.

■ ADRENALINE (EPINEPHRINE)

Caution Adrenaline products have different administration techniques. These products should not be prescribed to the same patient without training in their use. Pharmacists should ensure that patients are educated regarding the product differences upon dispensing.

Note The adrenaline devices should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at www.allergy.org.au).

Note Pharmaceutical benefits that have the form adrenaline (epinephrine) 150 microgram/0.3 mL injection, 0.3 mL pen device and pharmaceutical benefits that have the form adrenaline (epinephrine) 150 microgram/0.15 mL injection, 0.15 mL pen device are equivalent for the purposes of substitution.

Note Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see www.servicesaustralia.gov.au/HPOS) or by telephone by contacting Services Australia on 1800 888 333.

Note No increase in the maximum quantity or number of units may be authorised.

Note No applications for repeats will be authorised.

Authority Required

Acute allergic reaction with anaphylaxis

Treatment Phase: Initial sole PBS-subsidised supply for anticipated emergency treatment

Clinical criteria:

- Patient must have been assessed to be at significant risk of anaphylaxis by, or in consultation with a clinical immunologist; **OR**
- Patient must have been assessed to be at significant risk of anaphylaxis by, or in consultation with an allergist; **OR**
- Patient must have been assessed to be at significant risk of anaphylaxis by, or in consultation with a paediatrician; **OR**
- Patient must have been assessed to be at significant risk of anaphylaxis by, or in consultation with a respiratory physician.

The name of the specialist consulted must be provided at the time of application for initial supply.

Authority Required

Acute allergic reaction with anaphylaxis

Treatment Phase: Initial sole PBS-subsidised supply for anticipated emergency treatment

Clinical criteria:

- Patient must have been discharged from hospital or an emergency department after treatment with adrenaline (epinephrine) for acute allergic reaction with anaphylaxis.

Authority Required

Acute allergic reaction with anaphylaxis

Treatment Phase: Continuing sole PBS-subsidised supply for anticipated emergency treatment

Clinical criteria:

- Patient must have previously been issued with an authority prescription for any form of this drug for this indication.

adrenaline (epinephrine) 150 microgram/0.3 mL injection, 0.3 mL pen device

8697R	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
NP	2	0	0.00	*156.52	25.00	^a Adrenaline Jr Viatris [AF]	^a Anapen Junior 150 [XT]
						^a EpiPen Jr. [AL]	

adrenaline (epinephrine) 150 microgram/0.15 mL injection, 0.15 mL pen device

15359J	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer
NP	2	0	0.00	*156.52	25.00	^a Jext Jnr [KB]

■ ADRENALINE (EPINEPHRINE)

Caution Adrenaline products have different administration techniques. These products should not be prescribed to the same patient without training in their use. Pharmacists should ensure that patients are educated regarding the product differences upon dispensing.

Note The adrenaline devices should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at www.allergy.org.au).

Note Pharmaceutical benefits that have the form adrenaline (epinephrine) 300 microgram/0.3 mL injection, 0.3 mL pen device (Adrenaline Viatrix, Anapen 300 and EpiPen) and pharmaceutical benefits that have the form adrenaline (epinephrine) 300 microgram/0.3 mL injection, 0.3 mL pen device (Jext) are equivalent for the purposes of substitution.

Note Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see www.servicesaustralia.gov.au/HPOS) or by telephone by contacting Services Australia on 1800 888 333.

Note No increase in the maximum quantity or number of units may be authorised.

Note No applications for repeats will be authorised.

Authority Required

Acute allergic reaction with anaphylaxis

Treatment Phase: Initial sole PBS-subsidised supply for anticipated emergency treatment

Clinical criteria:

- Patient must have been assessed to be at significant risk of anaphylaxis by, or in consultation with a clinical immunologist; **OR**
- Patient must have been assessed to be at significant risk of anaphylaxis by, or in consultation with an allergist; **OR**
- Patient must have been assessed to be at significant risk of anaphylaxis by, or in consultation with a paediatrician; **OR**
- Patient must have been assessed to be at significant risk of anaphylaxis by, or in consultation with a respiratory physician.

The name of the specialist consulted must be provided at the time of application for initial supply.

Authority Required

Acute allergic reaction with anaphylaxis

Treatment Phase: Initial sole PBS-subsidised supply for anticipated emergency treatment

Clinical criteria:

- Patient must have been discharged from hospital or an emergency department after treatment with adrenaline (epinephrine) for acute allergic reaction with anaphylaxis.

Authority Required

Acute allergic reaction with anaphylaxis

Treatment Phase: Continuing sole PBS-subsidised supply for anticipated emergency treatment

Clinical criteria:

- Patient must have previously been issued with an authority prescription for any form of this drug for this indication.

adrenaline (epinephrine) 300 microgram/0.3 mL injection, 0.3 mL pen device

8698T	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
NP	2	0	0.00	*156.52	25.00	^a Adrenaline Viatrix [AF] ^a EpiPen [AL]	^a Anapen 300 [XT]

adrenaline (epinephrine) 300 microgram/0.3 mL injection, 0.3 mL pen device

15355E	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer
NP	2	0	0.00	*156.52	25.00	^a Jext [KB]